SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Biotech Short Candidates
An SI Board Since December 2000
Posts SubjectMarks Bans
897 95 0
Emcee:  tuck Type:  Unmoderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
747Trimeris is bumping up these days. The uptrend seemed to begin after Glaxo startuck-10/3/2005
746Message 20932102Miljenko Zuanic-1/9/2005
745Miljenko, you said 80%-90% excretion in the Valaution thread, but I can't fituck-1/8/2005
744>Moral: Watch the Form 4s< Ya, I put a lot of weight on what the insidersfred hayes-1/7/2005
743Thanks, I needed that. It prompted me to do a quick poke into EDGAR. Late 2003tuck-1/7/2005
742Somebody talk me out of it: I'll try. Don't do it. It's the percefred hayes-1/7/2005
741Becoming more convinced that GERN's recent run is largely based on fluff. Stuck-1/7/2005
740Studies by them say no problem there. But the problem that got ARDM, night-timetuck-1/6/2005
739nktr - Has the lung problem with Exubera been resolved?semi_infinite -1/6/2005
738Watching Nanogen (NGEN) get frothy on an issued patent, and Geron (GERN) get frotuck-1/6/2005
737<i>Should have mentioned this one last week.... :-)</i> :-( When yoDoc Bones-12/23/2004
736>> is in my US nda predictions as a no << not bad!scaram(o)uche-12/23/2004
735I had no idea why this one had been so strong lately.......is in my US nda predirkrw-12/23/2004
734EYET; there are other issues. Alcon expecting to launch RETAANE about mid-2005.tuck-12/22/2004
733>>Eyetech Pharmaceuticals target raised to $71 from $63 at Merrill Lynch tuck-12/22/2004
732I'd feel bad for talking you out of it, but you forgot to mention formattingrkrw-12/21/2004
731I think insurers may disappoint both NBIX and SEPR; you guys got any thoughts ontuck-12/18/2004
730I think insurers may disappoint both NBIX and SEPR; you guys got any thoughts ontuck-12/18/2004
729Agree with rkrw on both counts. I'm long all of OSIP, NBIX and SEPR. PeterBiomaven-12/17/2004
728<<OSIP's huge gap up on Iressa's failure to demonstrate survival brkrw-12/17/2004
727FWIW, BoA's target (yesterday) for OSIP, $92 - Message 20864026nigel bates-12/17/2004
726American Pharmaceutical Partners recently presented Phase II data, and anticipattuck-12/17/2004
725thanks for pulling together the posts. interesting dig, hope it paid for you.scaram(o)uche-11/24/2004
724<i>However, Extina (PDUFA in late November) may be questionable for some, hmpa-11/23/2004
723Glaxo is apparently going to enter the flu vaccine market next year, which won&#tuck-10/29/2004
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News